Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 303-315 , April 2008

Primary combined androgen blockade in localized disease and its mechanism

References 

  1. Huggins C, Hodges C. Studies on prostate cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Research. 1941;1:293–297
  2. Labrie F, Candas B, Gomez JL, et al. Can combined androgen blockade provide long-term control or piossible cure of localized prostate cancer?. Urology. 2002;60:115–119
  3. Akaza H, Labrie F, Namiki M. A way of thinking of a MAB therapy for local/locally advanced prostate cancer: the theory and recent evaluation. Japanese Journal of Cancer and Chemotherapy. 2007;34:657–669[article in Japanese]
  4. Mizokami A, Yeh SY, Chang C. Identification of 3′,5′-cyclic adenosine monophosphate response element and other cis-acting elements in the human androgen receptor gene promoter. Molecular Endocrinology (Baltimore, Md.). 1994;8:77–88
  5. Mizokami A, Chang C. Induction of translation by the 5′-untranslated region of human androgen receptor mRNA. The Journal of Biological Chemistry. 1994;269:25655–25659
  6. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Research. 1994;22:3181–3186
  7. Fukagai T, Namiki TS, Carlile RG, et al. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU International. 2006;97:1190–1193
  8. Abdel-Wahab M, Berkey BA, Krishan A, et al. Influence of number of CAG repeats on local control in the RTOG 86-10 protocol. American Journal of Clinical Oncology. 2006;29:14–20
  9. Klotz L, Correia A, Zhang W. The relationship between the androgen receptor CAG repeat polymorphism length and the response to intermittent androgen suppression therapy for advanced prostate cancer. Prostate Cancer and Prostatic Diseases. 2005;8:179–183
  10. Platz EA, Leitzmann MF, Rifai N, et al. Sex steroid hormones and the androgen receptor gene CAG repeat and subsequent risk of prostate cancer in the prostate-specific antigen era. Cancer Epidemiology, Biomarkers & Prevention. 2005;14:1262–1269
  11. Labrie F, Dupont A, Belanger A, et al. Treatment of prostate cancer with gonadotropin-releasing hormone agonists. Endocrine Reviews. 1986;7:67–74
  12. Mizokami A, Koh E, Fujita H, et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Research. 2004;64:765–771
  13. Labrie F, Dupont A, Belanger A, et al. Combination therapy with flutamide and castration (LH-RH agonist or orchiectomy) in advanced prostate cancer: a marked improvement in response and survival. Journal of Steroid Biochemistry. 1985;23:833–841
  14. Murphy WM, Soloway MS, Barrows GH. Pathologic changes associated with androgen deprivation therapy for prostate cancer. Cancer. 1991;68:821–828
  15. Smith DM, Murphy WM. Histologic changes in prostatic carcinomas treated with leuprolide (luteinizing hormone-releasing hormone effect): distinction from poor tumor differentiation. Cancer. 1994;73:1472–1477
  16. Armas OA, Aprikian AG, Melamed J, et al. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma. The American Journal of Surgical Pathology. 1994;18:979–991
  17. Vailancourt L, Têtu B, Fradet Y, et al. Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma. The American Journal of Surgical Pathology. 1996;20:86–93
  18. Japanese Urological Association, the Japanese society of pathology . General rule for clinical and pathological studies on prostatic cancer. 3rd ed.. Tokyo: Kanahara; 2001;
  19. Kitagawa Y, Koshida K, Mizokami A, et al. Pathological effects of neoadjuvant hormonal therapy help predict progression of prostate cancer after radical prostatectomy. International Journal of Urology. 2003;10:377–382
  20. Schulman CC, Debruyne FM, Forster G, et al. 4-year-follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Urology. 2000;38:706–713
  21. Cancer Registration Committee of the Japanese Urological Association . Clinicopathological statistics on registered prostate cancer patients in Japan: 2000 report from the Japanese Urological Association. International Journal of Urology. 2005;12:46–61
  22. Maeda O. Option and indication for early stage prostate cancer. Japanese Journal of Cancer and Chemotherapy. 2003;30:26–31[article in Japanese]
  23. Akaza H, Homma Y, Usami M, et al. Efficacy of primary hormonal therapy for localized or locally advanced prostate cancer: results of a 10-year follow-up. BJU International. 2006;98:573–579
  24. Egawa M, Misaki T, Imao T, et al. Retrospective study on stage B prostate cancer in the Hokuriku District, Japan. International Journal of Urology. 2004;11:304–309
  25. Ueno S, Namiki M, Fukagai T, et al. Efficacy of primary hormonal therapy for patients with localized and locally advanced prostate cancer: a retrospective multicenter study. International Journal of Urology. 2006;13:1494–1500
  26. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA: The Journal of the American Medical Association. 1998;280:969–974
  27. Johansson JE, Andren O, Andersson SO, et al. Natural history of early, localized prostate cancer. JAMA: The Journal of the American Medical Association. 2004;291:2713–2719
  28. Labrie F, Belanger A, Lun-The V, et al. Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Molecular and Cellular Endocrinology. 2002;198:77–87
  29. Meng MV, Elkin EP, Harlan SR, et al. Predictors of treatment after initial surveillance in men with prostate cancer: results from CaPSURE. The Journal of Urology. 2003;170:2279–2283
  30. Tanaka N, Hara H, Yamabe F, et al. Investigation on prostate re-biopsy and high-sensitivity PSA of prostate cancer patients receiving endocrine therapy. Japanese Journal of Urology. 2005;96:196;[article in Japanese]
  31. Akakura K, Ito H, Sato N. Intermittent androgen suppression for prostate cancer. Nippon Rinsho. Japanese Journal of Clinical Medicine. 2000;58(Suppl):289–291[article in Japanese]
  32. Mizokami A, Ueno S, Fukagai T, et al. Global update on defining and treating high-risk localizing prostate cancer with leuprolin: an Asian perspective. BJU International. 2007;99(suppl):6–9
  33. Kato T, Komiya A, Suzuki H, et al. Effect of androgen deprivation therapy on quality of life in Japanese men with prostate cancer. International Journal of Urology. 2007;14:416–421
  34. Korfage IJ, deKoning HJ, Habbema DF, et al. Side-effects of treatment for localized prostate cancer: are they valued differently by patients and healthy control?. BJU International. 2007;99:801–806
  35. Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. The Journal of Urology. 2003;169:2008–2012

PII: S1521-690X(08)00008-0

doi: 10.1016/j.beem.2008.01.007

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 2 , Pages 303-315 , April 2008

Article Tools

* Image Usage & Resolution